Verona Pharma plc
VRNA evidence brief
What we can confirm
- BioSniper Score:
- 8.3 / 10
- Lead Asset:
- Ensifentrine (nebulized) - asthma (Phase 3)
What it means
What to watch
Prepared research question
What matters most for VRNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2025.
Tracking 4 pipeline candidates · 21 clinical trials for Verona Pharma plc.
Run Verona Pharma plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Verona Pharma plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.06 · 6% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Verona Pharma plc's lead drug candidate?
Verona Pharma plc's most advanced tracked candidate is Ensifentrine (nebulized) - asthma (Phase 3) for Chronic Obstructive Pulmonary Disease; COPD.
Who is the CEO of Verona Pharma plc?
Chief Executive Officer is the chief executive officer of Verona Pharma plc (VRNA).
What therapeutic areas does Verona Pharma plc focus on?
Verona Pharma plc develops therapies across Oncology, Rare Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.